参附注射液：对心血管疾病药理作用的综述

Xu Fei-Fei, Xie Xiao-Fang, Hu Hai-Yan, Tong Rong-Sheng, Peng Cheng

State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Front Pharmacol. 2024 Feb 14;15:1279584. doi: 10.3389/fphar.2024.1279584. eCollection 2024.

Shenfu injection (SFI), composed of ginseng and aconite, is a Chinese patent developed from the classic traditional prescription Shenfu Decoction created more than 700 years ago. SFI has been widely used in China for over 30 years for treating cardiovascular diseases. The main components in it include ginsenosides and aconitum alkaloids. In recent years, the role of SFI in the treatment of cardiovascular diseases has attracted much attention. The pharmacological effects and therapeutic applications of SFI in cardiovascular diseases are summarized here, highlighting pharmacological features and potential mechanisms developments, confirming that SFI can play a role in multiple ways and is a promising drug for treating cardiovascular diseases.

参附注射液（SFI）由人参和附子组成，是一种源自700多年前经典传统方剂参附汤的中药专利制剂。参附注射液在中国已广泛应用30多年，用于治疗心血管疾病。其主要成分包括人参皂苷和乌头生物碱。近年来，参附注射液在心血管疾病治疗中的作用备受关注。本文总结了参附注射液在心血管疾病中的药理作用和治疗应用，重点介绍了其药理特性和潜在作用机制的进展，证实参附注射液可通过多种方式发挥作用，是一种有前景的心血管疾病治疗药物。